403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Ardiol Therapeutics Inc.
(MENAFN- Baystreet) 10:53 AM EST - ardiol Therapeutics Inc. : Announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial ("MAVERIC") evaluating Cardiol's lead drug candidate CardiolRxTM for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRxTM on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval. Cardiol Therapeutics Inc.
shares T are trading up $0.01 at $1.48.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment